Adjuvant targeted therapy for non-small cell lung cancer
Non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases with a wide range of possible targeted activating mutations. In this regard, a lot of attention is paid to such treatment of patients with NSCLC as adjuvant targeted therapy after radical surgical treatment, nowadays. The active...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
IP Habib O.N.
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1b1bd4636d484295a570f34b0f6e7870 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1b1bd4636d484295a570f34b0f6e7870 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1b1bd4636d484295a570f34b0f6e78702021-11-30T17:03:34ZAdjuvant targeted therapy for non-small cell lung cancer1815-14341815-1442https://doaj.org/article/1b1bd4636d484295a570f34b0f6e78702020-07-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/34961/23376https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases with a wide range of possible targeted activating mutations. In this regard, a lot of attention is paid to such treatment of patients with NSCLC as adjuvant targeted therapy after radical surgical treatment, nowadays. The active interest in this option is associated with several reasons: sufficient low efficacy of adjuvant chemotherapy, increased capabilities of molecular genetic methods to determine the activating mutations, extensive introduction of liquid biopsy into the clinical practice, as well as the results of the trials associated with the use of targeted therapy both in the treatment of advanced forms of NSCLC and in an adjuvant regimen. The results of such trials as SELECT, ADJUVANT/CTONG1104, ADAURA have shown the benefit of adjuvant targeted therapy in comparison with chemotherapy, placebo or historical control. The ability to identify circulating tumor DNA as a marker of minimal residual disease after surgical treatment, as well as the determination of the mutation profile using the minimally invasive method such as the fluid biopsy will allow achieving an even more personalized approach to the appointment of adjuvant therapy. All this makes the use of adjuvant targeted therapy a promising and effective treatment option.Konstantin K. LaktionovAleksei M. KazakovMarat G. GordievPavel V. KononetsBakhrom B. AkhmedovJulia N. MaevskaiaIP Habib O.N.articlenon-small cell lung canceradjuvant therapytargeted therapycirculating tumor dnaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 2, Pp 104-107 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
non-small cell lung cancer adjuvant therapy targeted therapy circulating tumor dna Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
non-small cell lung cancer adjuvant therapy targeted therapy circulating tumor dna Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Konstantin K. Laktionov Aleksei M. Kazakov Marat G. Gordiev Pavel V. Kononets Bakhrom B. Akhmedov Julia N. Maevskaia Adjuvant targeted therapy for non-small cell lung cancer |
| description |
Non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases with a wide range of possible targeted activating mutations. In this regard, a lot of attention is paid to such treatment of patients with NSCLC as adjuvant targeted therapy after radical surgical treatment, nowadays. The active interest in this option is associated with several reasons: sufficient low efficacy of adjuvant chemotherapy, increased capabilities of molecular genetic methods to determine the activating mutations, extensive introduction of liquid biopsy into the clinical practice, as well as the results of the trials associated with the use of targeted therapy both in the treatment of advanced forms of NSCLC and in an adjuvant regimen. The results of such trials as SELECT, ADJUVANT/CTONG1104, ADAURA have shown the benefit of adjuvant targeted therapy in comparison with chemotherapy, placebo or historical control. The ability to identify circulating tumor DNA as a marker of minimal residual disease after surgical treatment, as well as the determination of the mutation profile using the minimally invasive method such as the fluid biopsy will allow achieving an even more personalized approach to the appointment of adjuvant therapy. All this makes the use of adjuvant targeted therapy a promising and effective treatment option. |
| format |
article |
| author |
Konstantin K. Laktionov Aleksei M. Kazakov Marat G. Gordiev Pavel V. Kononets Bakhrom B. Akhmedov Julia N. Maevskaia |
| author_facet |
Konstantin K. Laktionov Aleksei M. Kazakov Marat G. Gordiev Pavel V. Kononets Bakhrom B. Akhmedov Julia N. Maevskaia |
| author_sort |
Konstantin K. Laktionov |
| title |
Adjuvant targeted therapy for non-small cell lung cancer |
| title_short |
Adjuvant targeted therapy for non-small cell lung cancer |
| title_full |
Adjuvant targeted therapy for non-small cell lung cancer |
| title_fullStr |
Adjuvant targeted therapy for non-small cell lung cancer |
| title_full_unstemmed |
Adjuvant targeted therapy for non-small cell lung cancer |
| title_sort |
adjuvant targeted therapy for non-small cell lung cancer |
| publisher |
IP Habib O.N. |
| publishDate |
2020 |
| url |
https://doaj.org/article/1b1bd4636d484295a570f34b0f6e7870 |
| work_keys_str_mv |
AT konstantinklaktionov adjuvanttargetedtherapyfornonsmallcelllungcancer AT alekseimkazakov adjuvanttargetedtherapyfornonsmallcelllungcancer AT maratggordiev adjuvanttargetedtherapyfornonsmallcelllungcancer AT pavelvkononets adjuvanttargetedtherapyfornonsmallcelllungcancer AT bakhrombakhmedov adjuvanttargetedtherapyfornonsmallcelllungcancer AT julianmaevskaia adjuvanttargetedtherapyfornonsmallcelllungcancer |
| _version_ |
1718406430320492544 |